Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
72 hedge funds and large institutions have $69.6M invested in Amicus Therapeutics in 2013 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 8 closing their positions.
895% more call options, than puts
Call options by funds: $935K | Put options by funds: $94K
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
24% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 21
3% more funds holding
Funds holding: 70 → 72 (+2)
1% more capital invested
Capital invested by funds: $69.2M → $69.6M (+$420K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$3.04M |
| 2 |
Morgan Stanley
New York
|
+$692K |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
+$683K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$628K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$468K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.31M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.23M |
| 3 |
JP Morgan Chase
New York
|
-$634K |
| 4 |
RA
Royce & Associates
New York
|
-$502K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$417K |
FOLD Hedge Fund Activity: Q3 2013 in Review
72 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q3 2013, worth a combined $69.6M — up 0.61% from $69.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new FOLD positions and 8 closed out — a net gain of 2 holders — while 26 added to existing stakes and 21 trimmed.
The largest buyer was UBS AM, adding an estimated $3.04M. The largest seller was Wellington Management Group, exiting entirely with an estimated $3.31M sold.
- 72 institutional investors held Amicus Therapeutics (FOLD) as of Q3 2013, up from 70 in Q2 2013.
- Funds reported $69.6M of Amicus Therapeutics stock for Q3 2013, up 0.61% quarter-over-quarter.
- 10 funds opened new Amicus Therapeutics positions in Q3 2013 and 8 closed out, a net change of +2 holders.
- The largest Amicus Therapeutics buyer in Q3 2013 was UBS AM, an estimated $3.04M added.
- The largest Amicus Therapeutics seller in Q3 2013 was Wellington Management Group, an estimated $3.31M sold.
Based on aggregated 13F filings for Q3 2013.